Accuracy of positron emission tomography and positron emission tomography‐CT in the detection of differentiated thyroid cancer recurrence with negative 131I whole‐body scan results: A meta‐analysis

The purpose of this review was to present a meta‐analysis aimed to evaluate the accuracy of positron emission tomography (PET) and PET‐CT for detecting recurrence of differentiated thyroid carcinoma (DTC) not identified by 131I whole‐body scintigraphy.

[1]  S. Filetti,et al.  Differentiated thyroid carcinoma: defining new paradigms for postoperative management. , 2013, Endocrine-related cancer.

[2]  L. Ceriani,et al.  Relationship between serum thyroglobulin and 18FDG‐PET/CT in 131I‐negative differentiated thyroid carcinomas , 2012, Head & neck.

[3]  T. Chaiwatanarat,et al.  Utility of 8F-FDG PET/CT in well differentiated thyroid carcinoma with high serum antithyroglobulin antibody. , 2011, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[4]  V. Lowe,et al.  Prognostic value of 18F-fluorodeoxyglucose-positron emission tomography in patients with differentiated thyroid carcinoma and circulating antithyroglobulin autoantibodies , 2011, Nuclear medicine communications.

[5]  D. Elashoff,et al.  Positron emission tomography and positron emission tomography‐CT evaluation for recurrent papillary thyroid carcinoma: Meta‐analysis and literature review , 2011, Head & neck.

[6]  Yanyan Gao,et al.  The role of TSH for 18F-FDG-PET in the diagnosis of recurrence and metastases of differentiated thyroid carcinoma with elevated thyroglobulin and negative scan: a meta-analysis. , 2010, European journal of endocrinology.

[7]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, International Coaching Psychology Review.

[8]  G. Pentheroudakis,et al.  Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Jaetae Lee,et al.  Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using 18F‐FDG PET/CT , 2010, Clinical endocrinology.

[10]  P. Lamy,et al.  Impact de la TEP/TDM au 18F-FDG dans la prise en charge des patients atteints de cancer thyroïdien différencié , 2010 .

[11]  Stephanie L. Lee,et al.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[12]  Shu-ye Yang,et al.  Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis , 2009, Nuclear medicine communications.

[13]  Nathaniel Rothman,et al.  International patterns and trends in thyroid cancer incidence, 1973–2002 , 2009, Cancer Causes & Control.

[14]  Seong-Jang Kim,et al.  Clinical implication of F-18 FDG PET/CT for differentiated thyroid cancer in patients with negative diagnostic iodine-123 scan and elevated thyroglobulin. , 2009, European journal of radiology.

[15]  Frank Buntinx,et al.  The evidence base of clinical diagnosis , 2008 .

[16]  D. Altman,et al.  Assessing Risk of Bias in Included Studies , 2008 .

[17]  Ben A. Dwamena,et al.  Meta-analytical Integration of Diagnostic Accuracy Studies in Stata , 2007 .

[18]  M. L. Cunha,et al.  [Diagnostic value of positron emission tomography/computed tomography with fluorine-18 fluordeoxyglucose in patients with differentiated thyroid gland carcinoma, high thyroglobulin serum levels and negative iodine whole body scan]. , 2007, Arquivos brasileiros de endocrinologia e metabologia.

[19]  G. Antoch,et al.  Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancer , 2007, European Radiology.

[20]  C. Bodet-Milin,et al.  Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma. , 2007, Surgery.

[21]  Badreddine Bencherif,et al.  18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  D. Lee,et al.  The clinical impact of18F-FDG PET in papillary thyroid carcinoma with a negative131I whole body scan: A single-center study of 108 patients , 2006, Annals of nuclear medicine.

[23]  A. Iagaru,et al.  2-Deoxy-2-[18F]fluoro-d-glucose-Positron Emission Tomography and Positron Emission Tomography/Computed Tomography Diagnosis of Patients with Recurrent Papillary Thyroid Cancer , 2006, Molecular Imaging and Biology.

[24]  A. Alzahrani,et al.  Role of [18F]fluorodeoxyglucose positron emission tomography in follow-up of differentiated thyroid cancer. , 2006, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[25]  E. Wardelmann,et al.  Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  M. Stokkel,et al.  The value of FDG-PET in the follow-up of differentiated thyroid cancer: a review of the literature. , 2006, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[27]  Mithat Gonen,et al.  Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. , 2006, The Journal of clinical endocrinology and metabolism.

[28]  Chao Ma,et al.  Possible explanations for patients with discordant findings of serum thyroglobulin and 131I whole-body scanning. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  Jonathan J Deeks,et al.  The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. , 2005, Journal of clinical epidemiology.

[30]  A. Alzahrani,et al.  Diagnostic accuracy of high-resolution neck ultrasonography in the follow-up of differentiated thyroid cancer: a prospective study. , 2005, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[31]  D. Ng,et al.  Initial experience in use of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in thyroid carcinoma patients with elevated serum thyroglobulin but negative iodine-131 whole body scans. , 2005, Singapore medical journal.

[32]  R Brian Haynes,et al.  EMBASE search strategies for identifying methodologically sound diagnostic studies for use by clinicians and researchers , 2005, BMC medicine.

[33]  David Goldenberg,et al.  The Role of Positron Emission Tomography/Computed Tomography in the Management of Recurrent Papillary Thyroid Carcinoma , 2005, The Laryngoscope.

[34]  I. Riphagen,et al.  Update of the FDG PET search strategy , 2004, Nuclear medicine communications.

[35]  J. Kievit,et al.  Diagnostic value of serum thyroglobulin measurements in the follow‐up of differentiated thyroid carcinoma, a structured meta‐analysis , 2004, Clinical endocrinology.

[36]  R. Moncayo,et al.  99mTc-EDDA/HYNIC-TOC and 18F-FDG in thyroid cancer patients with negative 131I whole-body scans , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[37]  Yen-Kung Chen,et al.  Compare FDG-PET and Tc-99m tetrofosmin SPECT to detect metastatic thyroid carcinoma. , 2003, Academic radiology.

[38]  C. Snyderman,et al.  Combined Positron Emission Tomography/Computed Tomography Imaging of Recurrent Thyroid Cancer , 2003, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[39]  C. Kao,et al.  F18‐Fluorodeoxyglucose Positron Emission Tomography in Detecting Metastatic Papillary Thyroid Carcinoma with Elevated Human Serum Thyroglobulin Levels But Negative I‐131 Whole Body Scan , 2003, Endocrine research.

[40]  S. Larson,et al.  Positron emission tomography in thyroid cancer management. , 2002, Seminars in roentgenology.

[41]  R. Görges,et al.  Preoperative Diagnostic Value of [18F] Fluorodeoxyglucose Positron Emission Tomography in Patients With Radioiodine-Negative Recurrent Well-Differentiated Thyroid Carcinoma , 2001, Annals of surgery.

[42]  L. Hooft,et al.  Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer. , 2001, The Journal of clinical endocrinology and metabolism.

[43]  R. Görges,et al.  Value of preoperative diagnostic modalities in patients with recurrent thyroid carcinoma. , 2000, Surgery.

[44]  O. Schober,et al.  Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study , 1999, European Journal of Nuclear Medicine.

[45]  H. Jadvar,et al.  Evaluation of suspected recurrent papillary thyroid carcinoma with [18F]fluorodeoxyglucose positron emission tomography. , 1998, Nuclear medicine communications.

[46]  O. Schober,et al.  Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans , 1998, Langenbeck's Archives of Surgery.

[47]  M. Dietlein,et al.  Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer , 1997, European Journal of Nuclear Medicine.

[48]  R. Utiger.  Follow-up of patients with thyroid carcinoma. , 1997, The New England journal of medicine.

[49]  R. Smallridge,et al.  Imaging in thyroid cancer. , 1996, Endocrinology and metabolism clinics of North America.

[50]  J A Swets,et al.  Measuring the accuracy of diagnostic systems. , 1988, Science.

[51]  H. Joensuu,et al.  Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[52]  I. Apostolova,et al.  Can 18F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan? , 2011, Annals of Nuclear Medicine.

[53]  DipSci MBChB Dch Fracp MM Kevin London BHB,et al.  Clinical and Pathological Factors Related to 18F-FDG-PET Positivity in the Diagnosis of Recurrence and/or Metastasis in Patients with Differentiated Thyroid Cancer , 2010, Annals of Surgical Oncology.

[54]  P. Grigsby,et al.  Combined [18F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography (FDG-PET/CT) for Detection of Recurrent, 131I-Negative Thyroid Cancer , 2007, Annals of Surgical Oncology.

[55]  M. Schlumberger.  [Papillary and follicular thyroid carcinoma]. , 2007, Annales d'endocrinologie.

[56]  A. Di Giorgio,et al.  Comparative evaluation of recombinant human thyrotropin-stimulated thyroglobulin levels, 131I whole-body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy. , 2006, The Journal of clinical endocrinology and metabolism.

[57]  R. Buchert,et al.  Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[58]  S. Larson,et al.  [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. , 1999, The Journal of clinical endocrinology and metabolism.

[59]  Gerta Rucker,et al.  Bmc Medical Research Methodology Open Access the Relationship between Quality of Research and Citation Frequency , 2006 .